Provided by Tiger Trade Technology Pte. Ltd.

ADC Therapeutics SA

1.04
+0.07497.76%
Post-market: 1.03-0.0099-0.95%17:29 EDT
Volume:3.92M
Turnover:3.85M
Market Cap:132.13M
PE:-1.57
High:1.05
Open:0.9755
Low:0.9600
Close:0.9651
52wk High:4.98
52wk Low:0.7796
Shares:127.04M
Float Shares:88.56M
Volume Ratio:2.06
T/O Rate:4.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6636
EPS(LYR):-1.1224
ROE:-705.53%
ROA:-19.57%
PB:-0.58
PE(LYR):-0.93

Loading ...

BUZZ-ADC Therapeutics falls on higher rates of serious side-effects in cancer trial

Reuters
·
Jun 04

ADC Therapeutics' Drug Regimen to Treat B-Cell Lymphoma Meets Primary Endpoint of Progression-Free Survival in Phase 3 Trial

MT Newswires Live
·
Jun 04

ADC Therapeutics Shares Plummet on Lymphoma Drug Trial Data, Possible Cost Cuts

Dow Jones
·
Jun 04

ADC Therapeutics’ Zynlonta combination shows survival efficacy in DLBCL

TIPRANKS
·
Jun 04

ADC Therapeutics says LOTIS-5 trial shows Zynlonta plus Rituxan improves PFS in relapsed DLBCL

Reuters
·
Jun 04

ADC Therapeutics - Plans Sbla Submission for Zynlonta Plus Rituximab in Q4 2026

THOMSON REUTERS
·
Jun 04

ADC Therapeutics - Zynlonta Plus Rituximab Achieves Statistical Significance on Primary Endpoint of Pfs in Lotis-5

THOMSON REUTERS
·
Jun 04

ADC Therapeutics Announces Results From Lotis-5 Phase 3 Confirmatory Clinical Trial of Zynlonta® in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

THOMSON REUTERS
·
Jun 04

ADC Therapeutics shareholders approve annual meeting proposals

Reuters
·
Jun 03

RBC Capital Reaffirms Their Buy Rating on ADC Therapeutics (ADCT)

TIPRANKS
·
May 11

ADC Therapeutics (ADCT) Receives a Buy from RBC Capital

TIPRANKS
·
May 05

Analysts Offer Insights on Healthcare Companies: ADC Therapeutics (ADCT), Evolus (EOLS) and Nuvation Bio (NUVB)

TIPRANKS
·
May 05

ADC Therapeutics SA reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 04

Switzerland's ADC Therapeutics beats Q1 revenue estimates

Reuters
·
May 04

ADC Therapeutics Q1 net loss narrows to $33 million; product revenue rises to $20 million

Reuters
·
May 04

BRIEF-ADC Therapeutics Q1 Income From Operations USD -25.245 Million Vs. IBES Estimate USD -23.6 Million

Reuters
·
May 04

ADC Therapeutics Sa - Lotis-5 Phase 3 Topline Data Expected Q2 2026; Full Lotis-5 and Lotis-7 Data by Year End

THOMSON REUTERS
·
May 04

ADC Therapeutics Q1 Basic EPS USD -0.21

THOMSON REUTERS
·
May 04

ADC Therapeutics Sa - Cash and Cash Equivalents $231.0 Mln as of March 31, 2026; Cash Runway Into 2028

THOMSON REUTERS
·
May 04

Press Release: ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates

Dow Jones
·
May 04